摘要
目的：探讨利妥昔单抗联合自体外周血干细胞移植(autologous peripheral blood stem cell transplan- tation,APBSCT)治疗CD20阳性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)的可行性和有效性。方法：对4例CD20阳性NHL病人进行了5次利妥昔单抗联合APBSCT的治疗。利妥昔单抗于使用动员药物的前2 d使用,375 mg·m^(-2)静脉注射1次,观察病人使用利妥昔单抗的不良反应、动员效果及移植后的造血重建、并发症、临床转归。结果：所有病人均对利妥昔单抗耐受良好,动员后可采得足量CD34^+细胞,植入后在8～11 d内达造血重建,粒缺期出现短暂低热,无出血表现。移植后所有病人已随访5～44 mo。结论：利妥昔单抗联合APBSCT治疗CD20阳性NHL是一种耐受良好及效果良好的方法。
AIM： To explore the feasibility and effectiveness of a regimen using rituximab combined with autologous peripheral blood stem-cell transplantation （APBSCT） in CD20 positive non-Hodgkin＇s lymphoma （NHL）. METHODS： Rituximab combined with APBSCT was performed for five times in four patients with CD20 positive NHL. Rituximab was used 375 mg·m^-2 intravenously once 2 d before the chemotheraphy. The adverse reactions of peritransplantation use of rituximab, the effect of mobilization, and hem-atopoietic reconstruction as well as complications and clinical outcome after transplantation in these patients were all observed and recorded. RESULTS： The use of rituximab could be tolareted well by each patient with adequate CD34^＋ cells after mobilization. The time of reaching hematopoietic reconstruction was 8 to 11 d. Each patient suffered a temporary fever during agranulocytosis but without bleeding. Posttransplantation follow-up was kept on for 5-44 mo after transplantation. CONCLUSION： Rituximab combined with APBSCT is a feasible and effective treatment for patients with CD20 positive NHL.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第7期541-544,共4页
Chinese Journal of New Drugs and Clinical Remedies
基金
江苏省基础研究重大招标项目(BK2004004)
江苏省社会发展资助项目(BS2003043)
江苏省卫生厅资助项目(H200313)
关键词
抗体
单克隆
造血干细胞移植
移植
自体
淋巴瘤
非霍奇金
利妥昔单抗
antibody, monocolonal
hematopoietic stem cell transplantation
transplantation, autologous
lymphoma, non-Hodgkin
rituximab
